Company Overview and News

KLCI edges up as regional markets stage recovery

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI edged up in early trade this morning in in line with the recovery at most regional markets.

KLCI down 0.66% as investor sentiment remains jittery

2018-06-22 theedgemarkets
KUALA LUMPUR (June 22): The FBM KLCI fell 0.66% at mid-morning today, tracking losses at the regional markets as investor sentiment remained jittery given the spectre of a global trade war.
APEXF 7090 UPBMF 4065 7235 BATS 4162 2089 9334 KLKBY 2445 4863 5347 1996 0026 TNABY MYTEF 2836 TNABF MGFCF

US-China trade spat continues to spook investors

2018-06-21 theedgemarkets
KUALA LUMPUR: The latest development in the Sino-American trade dispute continued to spook investors, sending the benchmark FBM KLCI to its eighth day of losses yesterday.
APEXF 3301 7090 BATS 4162 7022 9334 GBTKF

KLCI pares gains as regional sentiment turns tepid

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI pared its gains substantially at the midday break today, tracking its regional peers as China's stock markets fell.
HLFBF APEXF PBLOF 7090 UPBMF 1082 5681 BATS 4162 1295 2089 7077 5014 9598 KLKBY 2445 3301 2216 5819 MYPRY

KLCI rises 0.68%, tracks gains at regional markets

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI rose 0.68% at mid-morning today, tracking the rebound at most regional markets.
APEXF PBLOF 7090 UPBMF 4065 8621 7113 TPGVF 6521 7087 1295 2089 7077 5014 TGLVY KLKBY 2445 2216 5819 MYPRY 3719

Casualties of US-China trade war, Bursa extends loss

Stocks tumble: The Hang Seng Index closed at 29,468.15, a loss of 2.78, in Hong Kong yesterday. Hong Kong and Shanghai stocks led a sell-off across Asian and European markets on rising fears of a trade war after Trump threatened fresh tariffs on Chinese imports and Beijing warned of countermeasures. — AFP
APEXF PBLOF 7090 MLYBY MLYNF UPBMF 1295 2089 1155 BSMAF 3719 1929 1818

KLCI extends loss, drops 0.65% as banks drag

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI extended its loss at the midday break today and dropped 0.65%, dragged by banking heavyweights Public Bank Bhd and Malayan Banking Bhd (Maybank).
HLFBF APEXF PBLOF 7090 MLYNF 7113 4065 TPGVF 1295 2852 3026 3301 2836 MLYBY 1082 5681 0096 5202 7123 TGLVY 1155 4588 1996 0026 3719

KLCI down 0.42% in line with the regional pullback

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI was down 0.42% at mid-morning today, in line with the pullback at most regional markets as the tariff tit-for-tat between the US and China intensified.
HLFBF APEXF 7090 5150 4065 1082 5681 BATS 4162 5014 7123 3026 3867 1996 0026 MYPRY 3719

KLCI pares loss, down 0.78% as sentiment stays tepid

2018-06-18 theedgemarkets
KUALA LUMPUR (June 18): The FBM KLCI pared some of its losses at the midday break and was down 0.78%, with tepid sentiment tracking losses at the regional markets.
APEXF 7251 7090 7113 BATS TPGVF 4162 3034 KLKBY 5226 5347 3301 TNABY AXXTF HRGHY 5681 2291 1163 5168 TGLVY 2445 1996 6888 5819 TNABF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...